This being a UK company the price of a FISH test might become lower, and thus the NHS use these tests more frequently.
Cytocell Ltd. Of Cambridge, England, announced the availability of a new range of in vitro diagnostic tests to aid in detecting patients with Chronic Lymphocytic Leukaemia (CLL).
The new range of Cytocell CLL FISH probes includes the new CLL PROFILER Kit comprising of the P53/ATM Probe Combination and a newly developed D13S319/13qter/12cen Deletion/Enumeration probe. In total Cytocell has 19 different FISH probes specifically designed with the intention of detecting abnormalities of the most common genes linked with CLL.
Cytocell's Aquarius® CLL PROFILER kit detects cytogenetic abnormalities in bone marrow specimens and peripheral blood samples from patients with CLL. Deletions of ATM and TP53 are the most serious rearrangements involved in CLL and detection of deletions of these genes provides very important information as to the therapy choices for such patients, especially since deletions of TP53 and ATM provide a poor prognosis.
Fluorescence In Situ Hybridisation (FISH), uses locus-specific probes, which are capable of defining numerical and structural chromosome changes. This should now become a routine diagnostic test in the clinical laboratory and the technique has thus been shown to be useful in the management of CLL patients.